Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Integrated Diagnostics Holdings plc (IDGXF)
Saint Helier, JE
Integrated Diagnostics Holdings plc (IDGXF) functions as a consumer-focused healthcare enterprise, primarily dedicated to providing a comprehensive array of medical diagnostic services for patients. Its extensive service portfolio encompasses approximately 2,000 distinct diagnostic examinations, spanning diverse fields such as immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. The company maintains an operational footprint across Egypt, Jordan, Sudan, and Nigeria. By December 30, 2021, its network had grown to encompass 452 branch laboratories. Established in 1979, the organization's main office is situated in Saint Helier, Jersey.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -7.09% | -7.09% | -5.61% | -12.55% | +85.83% | +43.64% | -50.03% | -51.26% | -51.26% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Diagnostics & Research: +7.9%+37.3% ★ Q1'26: +28.7% (vs Q3'24)
-
EPS growth Medical - Diagnostics & Research: +30.8%+19.2% Q1'26: +59.6% (vs Q3'24)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+12.9% Q1'26: +6.8% (vs Q3'24)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+29.6% ★ Q1'26: +22.1% (vs Q3'24)
-
ROIC Medical - Diagnostics & Research: +5.2%+39.5% ★ Q1'26: +50.8% (vs Q3'24)
-
Share dilution Medical - Diagnostics & Research: 0.0%-2.1% ★ Q1'26: -1.0% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.56× ★ Q1'26: 0.74× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.01B
est: 1.04B (-2.9%)
|
1.17B
est: 1.18B (-0.5%)
|
1.51B
est: 1.50B (+1.2%)
|
1.92B
est: 1.87B (+2.5%)
|
2.23B
est: 2.41B (-7.7%)
|
2.66B
est: 2.59B (+2.5%)
|
5.22B
est: 4.92B (+6.2%)
|
3.61B
est: 3.41B (+5.8%)
|
4.12B
est: 3.93B (+4.8%)
|
5.72B
est: 5.45B (+5.0%)
|
7.86B
est: 7.58B (+3.6%)
|
9.73B
9.73B – 9.73B
+28.3% YoY
|
11.56B
11.56B – 11.56B
+18.8% YoY
|
12.88B
12.88B – 12.88B
+11.4% YoY
|
13.92B
13.92B – 13.92B
+8.1% YoY
|
| EBITDA |
316.41M
est: 415.32M (-23.8%)
|
442.54M
est: 467.43M (-5.3%)
|
630.74M
est: 594.89M (+6.0%)
|
806.60M
est: 744.78M (+8.3%)
|
972.62M
est: 958.82M (+1.4%)
|
1.22B
est: 1.03B (+18.6%)
|
2.57B
est: 1.96B (+31.4%)
|
1.06B
est: 1.35B (-21.5%)
|
1.28B
est: 1.56B (-18.1%)
|
2.09B
est: 1.99B (+4.9%)
|
2.89B
est: 2.78B (+4.2%)
|
3.56B
3.56B – 3.56B
+28.3% YoY
|
4.23B
4.23B – 4.23B
+18.8% YoY
|
4.72B
4.72B – 4.72B
+11.4% YoY
|
5.10B
5.10B – 5.10B
+8.1% YoY
|
| EBIT |
280.22M
est: 334.81M (-16.3%)
|
397.81M
est: 376.81M (+5.6%)
|
568.82M
est: 479.56M (+18.6%)
|
729.21M
est: 600.40M (+21.5%)
|
819.14M
est: 772.95M (+6.0%)
|
1.04B
est: 830.63M (+24.8%)
|
2.33B
est: 1.58B (+47.8%)
|
856.48M
est: 1.09B (-21.5%)
|
879.04M
est: 1.26B (-30.3%)
|
1.61B
est: 1.61B (+0.3%)
|
2.33B
est: 2.24B (+4.1%)
|
2.87B
2.87B – 2.87B
+28.3% YoY
|
3.41B
3.41B – 3.41B
+18.8% YoY
|
3.80B
3.80B – 3.80B
+11.4% YoY
|
4.11B
4.11B – 4.11B
+8.1% YoY
|
| Net Income |
144.87M
est: 250.31M (-42.1%)
|
260.40M
est: 287.03M (-9.3%)
|
374.02M
est: 358.94M (+4.2%)
|
502.09M
est: 469.63M (+6.9%)
|
510.93M
est: 561.53M (-9.0%)
|
594.02M
est: 614.15M (-3.3%)
|
1.41B
est: 1.47B (-4.1%)
|
541.11M
est: 573.29M (-5.6%)
|
510.30M
est: 528.51M (-3.4%)
|
1.08B
est: 967.23M (+11.4%)
|
1.26B
est: 1.24B (+1.5%)
|
1.58B
1.58B – 1.58B
+26.8% YoY
|
1.98B
1.98B – 1.98B
+25.4% YoY
|
2.31B
2.31B – 2.31B
+16.8% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
264.11M
est: 99.23M (+166.2%)
|
158.58M
est: 111.67M (+42.0%)
|
186.36M
est: 142.13M (+31.1%)
|
254.94M
est: 177.94M (+43.3%)
|
305.23M
est: 229.08M (+33.2%)
|
329.09M
est: 246.17M (+33.7%)
|
316.78M
est: 467.20M (-32.2%)
|
359.38M
est: 323.51M (+11.1%)
|
401.39M
est: 373.61M (+7.4%)
|
533.00M
est: 469.97M (+13.4%)
|
632.84M
est: 654.17M (-3.3%)
|
839.59M
839.59M – 839.59M
+28.3% YoY
|
997.28M
997.28M – 997.28M
+18.8% YoY
|
1.11B
1.11B – 1.11B
+11.4% YoY
|
1.20B
1.20B – 1.20B
+8.1% YoY
|
| EPS |
0.24
est: 0.42 (-43.1%)
|
0.44
est: 0.48 (-9.0%)
|
0.62
est: 0.60 (+2.5%)
|
0.84
est: 0.79 (+6.2%)
|
0.81
est: 0.95 (-14.4%)
|
0.99
est: 1.03 (-4.3%)
|
2.35
est: 2.48 (-5.3%)
|
0.90
est: 0.97 (-6.8%)
|
0.85
est: 0.89 (-4.5%)
|
1.82
est: 1.66 (+9.4%)
|
2.17
est: 2.14 (+1.5%)
|
2.71
2.71 – 2.71
+26.8% YoY
|
3.40
3.40 – 3.40
+25.4% YoY
|
3.97
3.97 – 3.97
+16.8% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hend El Sherbini | Group Chief Executive Officer & Executive Director | 29M | — |
| Sherif Mohamed Mohamed El Zeiny | Vice President, Group Chief Financial Officer & Executive Director | 19M | male |
| Tarek Yehia | Director of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IDGXF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
